ONO-4059 will be administered orally once daily after a meal.

2 trials

Sponsors

Terasawa Tetsuji

Conditions

Systemic Sclerosissteroid-resistant pemphigus

Phase 1

ONO-4059-08:ONO-4059 phase 1

Active, not recruitingJPRN-jRCT2031200315

Terasawa TetsujiSystemic Sclerosis

Start: 2021-03-30Target: 16Updated: 2026-06-29

Phase 3

ONO-4059-10:Phase 3 study in patients with steroid-resistant pemphigus

Active, not recruitingJPRN-jRCT2031220043

Terasawa Tetsujisteroid-resistant pemphigus

Start: 2022-08-15Target: 34Updated: 2026-09-14

Related Papers

An open-label randomized parallel-group phase I study of the oral Bruton tyrosine kinase inhibitor tirabrutinib in systemic sclerosis

British Journal of Dermatology2025-07-302 citations